The results of CIBIS-II, MERIT-HF, and US Carvedilol
stratified by heart failure etiology indicated a decrease in mortality in patients with both ischemic and nonischemic heart failure.
Groundbreaking clinical trial results have demonstrated that long-term treatment with the beta blocking agent carvedilol
following a heart attack can reduce the risk of patients having another heart attack by 41 percent and dying by 23 percent.
A study in 2003 in 3,029 patients with New York Heart Association class II-IV heart failure and an ejection fraction of less than 35% were randomized to 25 mg of carvedilol
twice daily or 50 mg of metoprolol tartrate (Lopressor) twice daily.
A temporary shortfall in the supply of carvedilol
may cause some patients to have difficulty filling their prescriptions, the drug's maker, GlaxoSmithKline, announced in a "Dear Healthcare Professional" letter.
Although the efficacy of bisoprolol, carvedilol
, and metoprolol has been documented in studies that compared each of these drugs against placebo, two of these agents were compared with each other in just one reported study, the Carvedilol
or Metoprolol European Trial (COMET) (Lancet 2003;362:7-13).
Limited Tenders are invited for Purchase Of Widal Test Kit Uristix (Bottle of 100), Tab Carvedilol
What the Experts Drug Cost/Day* Dosage Say** carvedilol
no generic up to 25 mg Available in trade [Coreg] available b.
Treatment with carvedilol
cut the incidence of new-onset microalbuminuria by 47%, compared with metoprolol, in a study of more than 700 patients with type 2 diabetes and hypertension.
Largest Head-to-Head Study Ever Reports on Efficacy of Carvedilol
Patients participating the Carvedilol
Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) study experienced a 40% reduction in fatal or nonfatal MI.
NEW ORLEANS -- Carvedilol
provides compelling metabolic advantages over metoprolol when used in combination with a renin-angiotensin system blocker in hypertensive diabetic patients, according to the results of a landmark clinical trial.
5, 1995-- Boehringer Mannheim Therapeutics (BMT) and SmithKline Beecham (SB) today announced the formation of a collaboration to sell carvedilol
in most markets worldwide.